Incidental finding of monoclonal gammopathy in blood donors: A follow-up study

Blood Transfusion

Volumn 10, Issue 3, 2012, Pages 338-343

  La Raja, Massimo ^a   Barcobello, Monica ^a   Bet, Nicola ^a   Dolfini, Paolo ^a   Florean, Marina ^a   Tomasella, Federica ^a   De Angelis, Vincenzo ^b   Mascaretti, Luca ^a  

^a UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Blood donor; MGUS; Monoclonal gammopathy; Multiple myeloma

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; M PROTEIN; PLASMA PROTEIN;

ADULT; AGED; ARTICLE; BLOOD BANK; BLOOD DONOR; ELECTROPHORESIS; FEMALE; FOLLOW UP; HUMAN; INCIDENTAL FINDING; KIDNEY DISEASE; LIGHT CHAIN DEPOSITION DISEASE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; SCREENING;

ADULT; AGED; BLOOD DONORS; BLOOD PROTEIN ELECTROPHORESIS; DONOR SELECTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PARAPROTEINEMIAS; RETROSPECTIVE STUDIES;

EID: 84865190439     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2012.0083-11     Document Type: Article

References (23)

1. Rajkumar SV. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management. Hematology Am Soc Hematol Educ Programm 2005: 340-5.
2. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564-9. (Pubitemid 34438817)
3. Fine JM, Lambin P, Derycke C, et al. Systematic survey of monoclonal gammapathies in the sera from blood donors. Transfusion 1979; 19: 332-5. (Pubitemid 9250366)
4. Beauplet A, Danic B, Aussant-Bertel F, et les médecins de l'EFS-Bretagne. Sélection médicale des candidats à un don de sang: biologie. Transfus Clin Biol 2003; 10: 469-81.
5. Raffaelli MS, Masci A, Porta E, et al. MGUS and blood donation Vox Sang 2007; 93 (Suppl. 1), 80-1.
6. Maisnar V, Tichý M, Øeháèek V et al. Monoclonal gammopathies in a series of 1743 plasma donors. Acta Medica (Hradec Králové) 2006; 49: 119-21.
7. Mollee P. Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies. Clin Biochem Rev 2009; 30: 93-103.
8. Kristinsson SY, Bjorkholm M, Andersson TM, et al. Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica 2009; 94: 1714-20.
9. Bida JP, Kyle RA, Therneau TN, et al. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clin Proc 2009; 84: 685-93.
10. Ogmundsdóttir HM, Haraldsdóttir V, Jóhannesson G, et al. Monoclonal gammopathy in Iceland: a population-based registry and follow-up. Br J Haematol 2002; 118: 166-73.
11. Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol 2002; 20: 1625-34. (Pubitemid 34260544)
12. Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc 2004; 79: 859-66. (Pubitemid 38879951)
13. Gregersen H, Mellemkjaer L, Ibsen JS, et al. The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. Haematologica. 2001; 86: 1172-9. (Pubitemid 33063863)
14. Rosiñol L, Cibeira MT, Montoto S, et al. Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size. Mayo Clin Proc 2007; 82: 428-34.
15. Van De Donk N, De Weerdt O, Eurelings M, et al. Lokhorst H. Malignant transformation of monoclonal gammopathy of undetermined significance: cumulative incidence and prognostic factors. Leuk Lymphoma 2001; 42: 609-18. (Pubitemid 32782767)
16. Rossi F, Petrucci MT, Guffanti A, et al. Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance. Clin Cancer Res 2009; 15: 4439-45.
17. González García ME, Fernández Álvarez C, Robles Marinas V, et al. Serie de 618 casos de gammapatías monoclonales de significado indeterminado (GMSI): factorespredictivos de desaparición del componentemonoclonal o de evolución a gammapatías malignas. Rev Clin Esp 2008; 208: 288-94.
18. Giraldo P, Rubio-Félix D, Delgado P, Giral M. [Transient monoclonal gammopathies. Study of 34 cases]. Sangre 1994; 39: 351-5.
19. Bird J, Behrens J, Westin J, et al., Haemato-oncology Task Force of the British Committee for Standards in Haematology, UK Myeloma Forum and Nordic Myeloma Study Group. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2009; 147: 22-42.
20. Bladé J, Rosiñol L, Cibeira MT, de Larrea CF. Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia 2008; 22: 1651-7.
21. Madan S, Greipp PR. The incidental monoclonal protein: current approach to management of monoclonal gammopathy of undetermined significance (MGUS). Blood Rev 2009; 23: 257-65.
22. Rajkumar SV, Kyle RA, Melton LI III, et al. Serum free light chain ratio as an indipendent risk factor for progression in monoclonal gammolpatht of undetermined significance. Blood 2005; 106: 812-7. (Pubitemid 41076419)
23. Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003; 102: 3759-64. (Pubitemid 37409398)